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ABSTRACT 39 
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia 40 
and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of 41 
the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed 42 
in t(4;11)+ B-cell acute lymphoblastic leukemia patients, but the reciprocal fusion A4M is expressed in only 43 
half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic 44 
differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic 45 
differentiation models to study whether the A4M fusion cooperates with MA4 during early human 46 
hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-47 
endothelial precursors, both endothelial- and hemogenic-primed. Double fusion-expressing hemato-48 
endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-49 
committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. 50 
Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions 51 
by RNA-seq and H3K79me3 ChIP-seq, respectively, confirmed a hematopoietic/endothelial cell 52 
differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, ChIP-seq 53 
analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A 54 
cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish 55 
a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic 56 
development. 57 
 58 
 59 
 60 
 61 
 62 
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INTRODUCTION 63 
The mixed-lineage leukemia (MLL) gene encodes for an H3K4 histone methyltransferase important in 64 
hematopoietic development1. The human MLL gene is frequently rearranged in acute leukemia and typically 65 
confers a dismal outcome2,3. Of particular interest is the translocation t(4;11)(q21;q23), which encodes the 66 
fusion proteins MLL-AF4 (MA4) and AF4-MLL (A4M), and is associated with infant B-cell acute lymphoblastic 67 
leukemia (B-ALL). This t(4;11)+ infant leukemia is characterized by a very brief latency, raising the question 68 
of how it evolves so quickly4. Moreover, the exceptionally high concordance rate of t(4;11)+ B-ALL in 69 
monozygotic twin infants5,6 suggests that all the necessary (epi)genetic events required for leukemogenesis 70 
are accomplished prenatally, during embryonic/fetal hematopoietic development7. However, our 71 
understanding of t(4;11)-mediated developmental effects is limited, at least in part, due to the variety of 72 
phenotypes and long latency observed in currently available t(4;11) mouse models2,8-17. These different 73 
phenotypes likely result from targeting a cell in the wrong developmental stage, or not addressing the impact 74 
of secondary hits, leaving open questions about the developmental impact of the t(4;11) translocation during 75 
early human development.  76 
 77 
The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative 78 
translocated chromosomes remains obscure in cancer. The MA4 fusion is always expressed in t(4;11)+B-79 
ALL patients, whereas the reciprocal fusion A4M is expressed in only half of the patients18-20. Importantly, 80 
t(4;11)+ cell lines display addiction to MA4 but not to A4M21,22, and although A4M was not sufficient to initiate 81 
leukemia in cord blood-derived CD34+ cells23, it was nevertheless capable of initiating B-ALL in mice without 82 
the requirement of MA4, indicating that it contributes to t(4;11)-driven leukemogenesis11,24,25. Strikingly, a 83 
very recent clinical study have unraveled an independent prognostic value for MA4 expression in t(4;11)+ 84 
infant B-ALL, thus adding a new piece to the puzzle19. Thus, the developmental/pathogenic contribution of 85 
the t(4;11)-resulting reciprocal fusion A4M remains enigmatic. 86 
4 
 
Human embryonic stem cells (hESCs) represent a powerful tool for modeling different developmental aspects 87 
of human disease that cannot otherwise be addressed by patient sample analyses or mouse models7,26,27. 88 
Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, modeling 89 
hematopoietic differentiation in hESCs may represent a promising in vitro approach to study the onset of 90 
hematopoiesis and the mechanisms underlying early human hematopoietic development7. During hESC 91 
differentiation, a primitive population of CD45- hemato-endothelial precursors (HEPs) arises and further 92 
differentiates into CD45+ hematopoietic and mature endothelial cells28-30. Beyond their pathogenic role in 93 
acute leukemias, the MLL gene has also been implicated in endothelial cell maturation31, and endothelial 94 
dysfunction was recently linked to disease outcomes in childhood leukemias32. We previously reported that 95 
MA4 favors the emergence of endothelial-primed HEPs but not hemogenic HEPs from hESCs10. Here, we 96 
took advantage of well-established hESC-based differentiation systems to study whether the A4M fusion 97 
cooperates with MA4 during early human hematopoietic and endothelial development. We report a functional 98 
and molecular cooperation between MA4 and A4M fusions, which results in an enhanced hemato-endothelial 99 
output during human embryonic development. 100 
 101 
 102 
 103 
 104 
 105 
 106 
 107 
 108 
 109 
 110 
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METHODS 111 
Vector construction and lentiviral transduction 112 
The cDNAs for MA4 and A4M were subcloned into the pRRL-EF1α-PGK-NEO vector11, 16. Both fusions have 113 
been described previously (FigS1A)11,23. We used the following lentivectors containing either neomycin or 114 
dTo for cell selection: pRRL-EF1α-PGK-NEO (empty vector;EV), pRRL-EF1α-MA4-PGK-NEO (MA4) and 115 
pRRL-EF1α-A4M-PGK-dTo (A4M). VSV-G-pseudotyped lentiviral particles were generated in 293T cells 116 
using standard transfection protocols and concentrated by ultracentrifugation33. hESCs were infected 117 
overnight with concentrated EV or MA4 lentivirus plus 8 μg/ml polybrene. Viral supernatants were washed 118 
away the next day, and EV- and MA4-transduced hESCs were then selected with G418 (50-100g/ml) for 119 
three weeks. For dual transduction of MA4 and A4M fusions, G418-resistant MA4-expressing hESCs were 120 
infected with A4M-expressing viruses. EV/G418-selected hESCs were also transduced with A4M alone. 121 
Transgene expression was confirmed for all the genotypes (Fig1). 122 
 123 
Human ESC culture and characterization of transgenic human ESC lines 124 
hESCs (AND1 line) were maintained undifferentiated on a layer of irradiated-hMSCs (iMSC) in complete KO-125 
DMEM medium containing 20% knockout serum replacement and 8 ng/mL basic fibroblast growth factor 126 
(bFGF)34, 35. The medium was changed daily, and cells were passaged weekly by dissociation with 1:1 127 
collagenase IV:Dispase. Cultures were visualized daily by phase contrast microscopy. Approval for hESC 128 
work was obtained from the Spanish National Embryo Ethical Committee. Pluripotency of transgenic hESCs 129 
was characterized by flow cytometry using antibodies against SSEA-3, SSEA-4 TRA-1-60 and TRA-1-81 (BD 130 
Biosciences)36. Expression of the pluripotency-associated transcription factors OCT4, NANOG, SOX2, 131 
CRIPTO, and DNMT3B as well as transgene expression (MA4 and A4M) were analyzed by qRT-PCR. 132 
TableS1 shows the primers and PCR conditions used23,37,38. 133 
6 
 
Hematopoietic differentiation from human ESCs by embryoid body formation. 134 
Undifferentiated hESCs were treated with collagenase IV:Dispase for 1 hr at 37ºC. For embryoid body (EB) 135 
formation, cells were transferred to low-attachment plates and incubated overnight in differentiation medium 136 
(DM; KO-DMEM supplemented with 20% FBS, 1% nonessential amino acids, 1 mmol/L L-glutamine, and 0.1 137 
mmol/L -mercaptoethanol). The medium was changed next day to the same DM supplemented with the 138 
following hematopoietic cytokines: 300 ng/mL stem cell factor (SCF), 300 ng/mL Flt3L, 10 ng/mL interleukin 139 
(IL)-3, 10 ng/mL IL-6, 50 ng/mL granulocyte-colony stimulating factor (G-CSF) and 25 ng/mL bone 140 
morphogenetic protein 4 (BMP-4) (all from R&D)9,29,39-41. EBs were dissociated at different time points during 141 
development using collagenase B and enzyme-free Cell Dissociation Buffer (Invitrogen). Dissociated cells 142 
were stained with anti-CD34-PE, anti-CD31-FITC, anti-CD45-APC or anti-CD34-PE-Cy7, CD31-BV510, anti-143 
Glycophorin A, anti-CD43-FITC, anti-CD45-APC antibodies (all from BD Biosciences) and 7-actinomycin D, 144 
and analyzed using a FACS Canto flow cytometer9,29,39-41. Colony-forming unit (CFU) assays were performed 145 
at day 10 and 15 of EB differentiation by plating 60x104 EB cells onto serum-free methylcellulose H4435 146 
(Stem Cell Technologies). Colonies were scored after 12 days9,29,42-44. 147 
 148 
Cell cycle and apoptosis analysis  149 
For cell cycle analysis of hESC-derived HEPs and CD45+ cells, day 15 EBs were dissociated and harvested 150 
cells were fixed overnight in 70% ice-cold ethanol. Cells were then washed in PBS and incubated with anti-151 
CD31-FITC, anti-CD34-PE-Cy7 and anti-CD45-APC antibodies for 15 min. Cells were then suspended in 152 
propidium iodide-containing buffer and acquired-analysed on a FACS Canto-II using Modfit LT4.0 software, 153 
discriminating between quiescent cells (G0/G1), cycling cells (S-phase) and G2/M cells45,46. Apoptosis was 154 
assessed with the Annexin-V apoptosis detection kit (BD Biosciences)16.  155 
 156 
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Human ESC-OP9 co-cultures 157 
hESC-OP9 co-cultures were performed as described47,48. OP9 stroma was prepared by plating OP9 cells in 158 
gelatin-coated dishes, and allowing them to overgrow as a monolayer. hESCs were prepared as a suspension 159 
of small aggregates using collagenase IV:Dispase. One-tenth of this suspension was plated on top of the 8-160 
day overgrown OP9 stroma. Media was replaced on the next day and one-half volume media changes were 161 
performed every other day thereafter. Hematopoietic differentiation was assessed by flow cytometry at day 162 
9 of co-culture. Accordingly, hESC-OP9 co-cultures were treated with collagenase IV/TrypLE and cells were 163 
dissociated and filtered through a 70-µm strainer. Cell suspensions were stained with anti-mouse CD29-164 
FITC and anti-human CD34-PE and CD45-APC antibodies. The proportion of HEPs (CD34+CD31+CD45-), 165 
and total blood cells (CD45+) was analyzed within the CD29- human ESC-derived cell population. Hemogenic 166 
and endothelial HEPs were distinguished based on CD34 and CD43 expression40. 167 
 168 
Culture of FACS-isolated HEPs in MS5 stroma or liquid culture 169 
Day 9 human hESC-OP9 co-cultures were dissociated as above and both CD45+ cells and HEPs were 170 
analyzed. FACS-purified HEPs (CD29-CD34+CD31+CD45-) were plated onto MS5 stroma or in liquid culture 171 
for 30 or 16 days, respectively, in DM with hematopoietic cytokines (50 ng/mL SCF, 50 ng/mL Flt3L, 10 ng/mL 172 
IL-3,20 ng/mL IL-7). The medium was changed every 7 days, and the emergence of CD45+ hematopoietic 173 
cells was analyzed by FACS. 174 
 175 
Endothelial differentiation of HEPs  176 
HEPS (2×104) from day 9 human hESC-OP9 co-cultures were seeded onto 0.1% gelatin-coated plates in 177 
complete EGM-2 medium with microvasculature supplements (Lonza) for 7 days. Cells were then fixed, 178 
permeabilized and stained with rabbit anti-human VE-cadherin (Cayman), mouse anti-human eNOS (BD 179 
Biosciences), and mouse anti-human vWF (DAKO) followed by Alexa488-conjugated anti-rabbit or Cy3-180 
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conjugated anti-mouse (Jakson Immunoresearch) antibodies. Nuclei were counterstained with DAPI. Images 181 
were obtained using an inverted fluorescence microscope. Day 7 differentiating cells were trypsinized and 182 
cell suspensions were stained with anti-human CD31-FITC and CD144-PerCP-Cy5.5 antibodies. 183 
 184 
Mouse transplantation and analysis of hematopoietic-endothelial engraftment  185 
NOD/LtSz-scid IL-2Rγ−/− (NSG) mice were housed under sterile conditions. The Animal Care Committee 186 
approved all mouse protocols. Briefly, cord bood-derived CD34+ HSPCs (3×104 cells) or cells from day 15 187 
EBs (5×105 cells) were intra-bone marrow (BM)-transplanted as described49. Animal health was monitored 188 
throughout the entire experiment. Mice were killed 10 weeks after transplantation and cell suspensions were 189 
analyzed by FACS for human chimerism using anti-HLA-ABC-FITC, anti-CD31-PE, CD144-PerCP-Cy5.5, 190 
and anti-CD45-APC antibodies. 191 
 192 
Statistical analysis 193 
All data are expressed as mean±SEM. Statistical comparisons were performed using the GraphPad Prism 194 
software with the nonparametric Mann-Whitney test, two-tailed P-value (95% confidence interval). Statistical 195 
significance was defined as a p-value<0.05. 196 
 197 
Online methods show detailed information about RNA- and Chromatin Immunoprecipitation sequencing and 198 
analysis. 199 
  200 
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RESULTS 201 
Co-expression of A4M and MA4 does not hijack pluripotency 202 
We showed very recently that only 45% of t(4;11)+ B-ALL patients express the reciprocal fusion A4M, 203 
whereas MA4 is consistently expressed in all t(4;11)+ B-ALL patients (Fig1A)18-20. Here, we generated 204 
transgenic hESC lines expressing “MA4 alone”, “A4M alone” or MA4+A4M (double fusion, Fig1B, S1B). EV 205 
(control)- and MA4-hESCs were established by G418 selection9. G418-resistant EV- or MA4-expressing 206 
hESCs were then transduced with A4M/dTo-expressing lentiviruses and >90% transduction efficiency was 207 
achieved. Transgenic hESC lines were maintained for >50 passages and retained human ESC-like 208 
morphology (Fig1B, left), transgene expression (Fig1B, right), and expression of pluripotency-associated 209 
transcription factors (Fig1C) and surface markers (Fig1D). All hESC genotypes formed teratomas in NSG 210 
mice (data not shown)9, 50. Thus, (co-)expression of A4M and/or MA4 is compatible with hESC pluripotency. 211 
 212 
A4M and MA4 co-operate to promote HEPs emergence and enhance blood production 213 
Hematopoietic differentiation was assessed using two distinct and well-established differentiation systems: 214 
EB formation43,47 (Fig2) and OP9 co-culture47,48 (Fig3). During differentiation, a population of primitive HEPs 215 
arises, which is responsible for further hematopoietic and endothelial commitment10,30 (Fig2A,3A). We 216 
investigated whether co-expression of A4M and MA4 impacts hESC-derived hematopoiesis by analyzing the 217 
emergence of HEPs during EB development in hESCs individually expressing the single fusions or the double 218 
fusion. We observed a pronounced (~5-10-fold; p<0.05) increase in HEPs at day 7 and 10 of development in 219 
EBs expressing the double A4M and MA4 fusion over single fusions (Fig2B, upper-left panel). We next 220 
assessed whether co-expression of A4M and MA4 influences subsequent hematopoietic commitment of 221 
HEPs. The kinetics of emergence and output of both total CD45+ hematopoietic cells and CD45+CD34+ 222 
hematopoietic progenitors was faster (EB day 10) from double fusion-expressing hESCs than from equivalent 223 
single fusion-expressing cells, achieving a 2-3-fold higher hematopoietic output by day 15 of EB development 224 
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(Fig2B). Furthermore, double fusion-expressing HEPs massively accelerated (EB day10) the emergence of 225 
clonogenic hematopoietic progenitors as compared to single fusion-expressing HEPs (Fig2B, bottom-right 226 
panel). According to our previous work, if the kinetics of hEB differentiation are extended allowing for a 227 
continuum HEP-to-blood transition, MA4-expressing hEBs display an enhanced HEP production coupled to 228 
an impaired blood output (EB day 20, Fig S2A) and clonogenic potential (EB day 15, Fig 2B). We confirmed 229 
stable expression of ectopic MA4 and A4M upon EB differentiation, supporting the link between genotype 230 
and phenotype (Fig2C).  231 
 232 
We also investigated hematopoietic differentiation using the OP9 differentiation system (Fig3A,B), and by 233 
plating FACS-sorted HEPs in either hematopoietic liquid culture (Fig3C) or onto MS5 feeders (Fig3D). After 234 
10 days on OP9 stroma, double fusion-expressing hESCs yielded a 10-fold higher number of CD45+ 235 
hematopoietic cells than did single fusion-expressing hESCs (Fig3B). Moreover, when HEPs were FACS-236 
sorted from day 9 OP9 co-cultures and allowed to differentiate into CD45+ blood cells, the yield of CD45+ 237 
cells was up to 60-fold higher in double fusion-expressing HEPs than in single fusion-expressing HEPs. 238 
(Fig3C,D). Encouraged by these results, we next investigated whether ectopic expression of both A4M and 239 
MA4 confers in vivo engraftment capacity to hESC-derived hematopoietic derivatives. To do this, we 240 
transplanted 5×105 hESC hematopoietic derivatives from each genotype into myeloablated NSG mice4,43,47, 241 
finding that, despite regulating hematopoietic development in vitro, double fusion-expression did not confer 242 
in vivo engraftment to hESC hematopoietic derivatives (Fig2D).   243 
 244 
The increased hematopoietic output of double fusion-expressing hESCs might be the consequence of 245 
transgene-mediated proliferation/survival of the emerging HEPs or CD45+ cells. To address this, we 246 
analyzed cell cycle distribution (FigS2B) and apoptosis (FigS2C) within both HEPs and the CD45+ cell 247 
population. No differences in the proportion of either cycling HEPs or CD45+ cells were detected between 248 
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genotypes (25–36% for HEPs and 35–41% for CD45+ cells; FigS2B). Apoptotic levels were similarly low 249 
between the different genotypes of HEPs (6–8%) and CD45+ cells (5–7%) (FigS2C). Collectively, these 250 
results show that A4M cooperates with MA4 to induce HEP specification and blood commitment, without 251 
hijacking proliferation or survival of HEPs.  252 
 253 
A4M and MA4 co-operate to enhance endothelial cell fate from HEPs 254 
We next addressed the developmental impact of A4M in endothelial maturation from HEPs10,47. We 255 
hypothesized that co-expression of A4M and MA4 in HEPs may (i) concomitantly promote subsequent 256 
endothelial and hematopoietic commitment or (ii) skew the hemato-endothelial commitment in favor of 257 
hematopoiesis. To test this, we analyzed the ability of HEPs to differentiate into mature endothelial cells. 258 
OP9-hESC co-cultures were dissociated on day 9 of development and HEPs were FACS-sorted and cultured 259 
for a week in endothelial-promoting conditions (Fig4A). The expression of the mature endothelial markers 260 
VE-cadherin (CD144), vWF, eNOS and CD31 was then analyzed. Irrespective of the genotype, HEPs 261 
cultured in endothelial conditions attached, became spindle-shaped, and formed VE-Cad+ endothelial-like 262 
structures co-expressing eNOS, vWF and CD31 (Fig4B,C, top panel). However, double fusion-expressing 263 
HEPs were more prone to differentiate into mature endothelial cells than single fusion-expressing HEPs. 264 
Accordingly, they yielded a 20-fold higher number of VE-Cad+ endothelial-like structures (Fig4C, top panel) 265 
and CD144+CD31+ endothelial cells (Fig4C, bottom panel). Interestingly, endothelial cells 266 
(HLA.ABC+CD31+CD34+CD144+CD45-CD43-) were found in the BM of mice transplanted with double fusion-267 
expressing hESC blood derivatives at levels ~4-fold higher than in mice transplanted with single fusion-268 
expressing cells (Fig4D). 269 
 270 
Within CD34+CD31+CD45- HEPs, two subpopulations of phenotypically and functionally distinct HEPs can be 271 
distinguished based on the expression of CD34 and CD43: hemogenic HEPs (CD34low/+CD43+CD45-) and 272 
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endothelial HEPs (CD34++CD43-CD45-) (Fig5A)40,48,51. We thus analyzed the contribution of both HEP 273 
populations to the superior hematopoietic and endothelial differentiation observed in double fusion-274 
expressing HEPs. Co-expression of A4M and MA4, but not single fusions, robustly enhanced the emergence 275 
of both endothelial and hemogenic HEPs (Fig5B,C). The identity of hemogenic and endothelial HEPs was 276 
confirmed by the specific expression of early hematopoietic and endothelial master genes (Fig5D). Thus, 277 
A4M cooperates with MA4 to promote hematopoietic and endothelial cell fate. 278 
 279 
Genome-wide transcriptomic and H3K79 methylation profiles support the developmental cooperation 280 
between A4M and MA4 281 
To identify patterns of gene expression that might molecularly explain the functional co-operation between 282 
A4M and MA4 in hematopoietic specification, we performed RNA-seq analysis on FACS-purified EV-, MA4, 283 
A4M- and double fusion-expressing HEPs from day 15 hEBs. Fig6A shows a heatmap representation of the 284 
hierarchical clustering of the 335 genes differentially expressed between the four genotypes (TableS2). 285 
There is a clear transcriptomic transition towards a hematopoietic/endothelial gene signature from EV-HEPs 286 
to double-fusion-expressing HEPs. Single fusion-expressing HEPs clustered interspersed between EV and 287 
double-fusion HEPs. The biological functions affected by genes differentially expressed in MA4-, A4M- and 288 
double fusion-expressing HEPs relative to EV were classified by IPA software47,52 and among the top 289 
significant enriched functional categories were “hematological system development and function”, “cancer” 290 
and “hematological disease” (Fig6B). Statistical (-log(p-value)) power shows distant effects of MA4 and A4M; 291 
however, co-expression of both fusions seems to establish a molecular balance/developmental cooperation 292 
in promoting blood-endothelial specification from hPSCs. Strikingly, biofunctions specifically associated to 293 
hematological lymphoid malignancies (not with non-hematological cancer) were predicted to be activated 294 
(positive z-score) exclusively in double fusion-expressing HEPs, further suggesting a molecular cooperation 295 
between MA4 and A4M in development and infant leukemia. (Fig6C). 296 
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The C-terminal-partners of MLL fusions normally interact with the histone methyltransferase DOT1L, which 297 
is the sole histone methyltransferase catalyzing histone 3 lysine 79 (H3K79) methylation, a chromatin 298 
modification widely associated with the dysregulated expression of HOX-A cluster genes in MLL leukemias 299 
13, 53. We thus performed genome-wide ChIP-seq analysis of the H3K79 trimethylation (H3K79me3) profiles 300 
in control, MA4-, A4M- and double fusion-expressing hESC-derived blood derivatives (Fig7,S3A, TableS3). 301 
In line with the RNA-seq data, functional analysis of the differential H3K79me3 peaks specific for double 302 
fusion-expressing cells revealed significant GO functional categories associated with ”definitive 303 
hematopoiesis”, “myeloid and erythroid differentiation/homeostasis” and “endothelial cell development” 304 
(Fig7A,S3B). This further supports the developmental co-operation between A4M and MA4 in promoting 305 
hemato-endothelial specification. 306 
 307 
Finally, we analysed the H3K79me3 profiles at genomic loci of the classical MLL target genes reported by 308 
Guenther et al54. Non-HOX-A classical MLL targets such as RUNX1, LMO2, ADMA10, and KDM6A showed 309 
a slight although non-significant, enrichment of H3K79me3 in MA4-expressing hESCs, validating our ChIP-310 
seq approach (Fig7B). However, enrichment of H3K79me3 in HOX-A cluster genes was observed 311 
exclusively in A4M-expressing cells although it was statistically significant only in double fusion-expressing 312 
differentiating hESCs (FDR<0.1) (Fig7C). As such, HOX-A genes were up-regulated in double-fusion-313 
expressing hematopoietic clonogenic progenitors (FigS3C). No differential enrichment of the repressive 314 
H3K4me2/3 mark was observed in either HOX-A or non-HOX genes in double fusion-expressing cells 315 
(FigS4). Collectively, these data suggest that the deregulated expression of HOX-A genes in MLL leukemias 316 
may be imposed by the reciprocal A4M fusion through a H3K79 methyltransferase activity. In support of this, 317 
a recent RNA-seq study performed in 42 infants with t(4;11)+ B-ALL enrolled in the Interfant treatment 318 
protocol, reveal that 45% of t(4;11)+ patients express the A4M fusion, and that HOX-A cluster genes are 319 
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exclusively expressed in this AF4-MLL-expressing subgroup of t(4;11)+ patients, who in fact display a 320 
significant more favorable clinical outcome19. 321 
 322 
DISCUSSION 323 
 324 
From an etiological and pathogenesis standpoint, infant cancer is distinct to adult cancer and should be 325 
studied as a developmental disease4,7,16. A biologically and clinically intriguing infant cancer is the t(4;11)+ 326 
B-ALL, which is associated with a dismal outcome4,21,23. Evidence in support of its prenatal origin comes from 327 
studies in monozygotic twins and archived blood spots, providing compelling evidence of a single prenatal 328 
cell as the origin for t(4;11)5, and also from recent genome-wide studies demonstrating that this infant 329 
leukemia has one of the lowest frequencies of somatic mutations of any sequenced cancer55. The stable 330 
genome of these patients suggests that in infant developmental cancer, one “big-hit” might be sufficient for 331 
overt disease, supporting a key contribution of the prenatal cell-of-origin during a critical developmental 332 
window of stem cell vulnerability in leukemogenesis. However, despite its aggressiveness and short latency, 333 
our current understanding about its etiology, pathogenesis and cellular origin is still limited2,4,16,52. Importantly, 334 
a recently developed xenograft model which represents the most bona fide model for t(4;11)+ B-ALL so far, 335 
has revealed the instructive role of MLL-Af4 in cord blood-derived CD34+ cells14. 336 
 337 
Studies using primary cells from t(4;11)+ B-ALL patients are incapable of addressing the developmental 338 
genesis of the hematopoietic system. Recent data suggest that fetal liver lymphoid-primed multipotent 339 
progenitor may provide the developmental prerequisites for the initiation of t(4;11)+/MLL-AF4 infant 340 
leukemia56. Because leukemogenesis manifests as a blockage or altered cell differentiation, the 341 
hematopoietic differentiation of hESCs may represent a promising in vitro model to study the onset of 342 
hematopoiesis and the earliest events leading to the specification of the hematopoietic cells36. Previous 343 
studies have addressed the oncogenic role of leukemic fusion genes in hESC-derived hematopoiesis57,5859. 344 
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We previously explored the developmental impact of the pre-natal fusion MA4 in hESC hemato-endothelial 345 
development10, and found that MA4 expression promotes the emergence of endothelial-primed HEPs and 346 
further endothelial commitment, but hijacks the specification of hemogenic-primed HEPs, impairing 347 
hematopoietic output10. 348 
 349 
The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative 350 
translocated chromosomes remains obscure in cancer18,60. The MA4 fusion is always expressed in t(4;11)+B-351 
ALL patients, whereas the reciprocal fusion A4M is expressed in only 45-50% of the patients18,60,19,20. Here, 352 
we took advantage of well-established hESC-based differentiation systems to study whether the A4M fusion 353 
cooperates with MA4 during early human hematopoietic and endothelial development. Co-expression of A4M 354 
and MA4 strongly promoted the emergence of HEPs, both endothelial-primed and hemogenic-primed. 355 
Moreover, the double fusion-expressing HEPs specified into significantly higher numbers of both 356 
hematopoietic and endothelial cells, irrespective of the in vitro differentiation protocol used and without 357 
affecting survival or proliferation, indicating a functional (developmental) co-operation between MA4 and A4M 358 
fusions during human hematopoietic development. This notion was confirmed by genome-wide 359 
transcriptomic analysis of differentiating HEPs. These developmental biology studies support previous 360 
evidence suggesting that A4M contributes to the pathobiology of t(4;11)+ B-ALL. Accordingly, Bursen11 361 
reported that A4M-transduced murine hematopoietic stem cells (HSCs) developed pro-B-ALL, whereas co-362 
transduction with MA4 and A4M resulted in mixed lineage leukemia. Moreover, studies from Milne’s 363 
laboratory demonstrated that RUNX1 is directly activated by MA4 and the RUNX1 protein interacts with the 364 
A4M protein, suggesting a mechanism of co-operation between the two fusion genes at the molecular level25. 365 
 366 
In the embryo, definitive hematopoiesis cannot occur in the absence of endothelial cell development. 367 
Definitive HSCs in both mouse and human emerge from the hemogenic endothelium by a process known as 368 
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endothelial-to-hematopoietic transition61. Hematopoietic differentiation of hESCs occurs through the 369 
generation of HEPs, from which then originate both endothelial and hematopoietic cells. Here, co-expression 370 
of A4M and MA4 in HEPs concomitantly promoted endothelial and hematopoietic commitment rather than 371 
skewing the hemato-endothelial commitment in favor of one lineage over the other. This finding is important 372 
because beyond their pathogenic role in acute leukemias, the MLL gene is implicated in endothelial cell 373 
maturation, and endothelial dysfunction was recently linked to disease outcome in childhood leukemias31,32. 374 
Furthermore, other leukemia fusion oncogenes as well as lymphoma-specific genetic aberrations have been 375 
found in endothelial cells from chronic myeloid leukemia and B-cell lymphoma patients10,43,44, suggesting that 376 
endothelial cells may be part of the neoplastic clone. Also, BM-derived mesenchymal stem cells (BM-MSCs) 377 
from infant t(4;11)+ B-cell ALL were recently found to harbor and express the t(4;11) translocation33. The 378 
existence of a common embryonic precursor for MSCs and endothelial cells has been recently demonstrated 379 
by hESC-directed differentiation10,45. The finding of such a common embryonic precursor, and the presence 380 
of t(4;11) in both leukemic blasts and BM-MSCs of infant patients, suggests that the t(4;11) translocation 381 
arises and has a developmental impact on early pre-hematopoietic precursors. As a technical caveat, it is 382 
important to emphasize that MA4 and A4M were sequentially transduced to allow for antibiotic selection and 383 
homogeneously-transduced hESC cultures. However, in double-fusion-expressing differentiating blood cells, 384 
MA4 was never individually expressed in the absence of A4M. When hematopoietic differentiation of hESCs 385 
was induced by EB formation both fusions were readily co-expressed, ruling out a biased functional 386 
phenotype driven by the sequential expression of each transgene in distinct developmental windows. 387 
 388 
 389 
Mechanistically, a putative function of A4M is to activate chromatin, rendering a chromatin landscape similar 390 
to that during stem cell development. It is currently unknown how A4M is able to reprogram chromatin, but it 391 
does contain the SET domain disrupted from its "specification domain", the N-terminal portion of MLL, which 392 
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binds to MEN1 and LEDGF, shaping the gene targeting module of the MLL gene. When A4M is expressed, 393 
the N-terminal portion is substituted by the AF4 N-terminus, which is the crucial domain (AF4N) that binds to 394 
and strongly activates RNA polymerase II (RNAP II) for transcriptional elongation. Overexpression of either 395 
AF4, AF4N or the fusion protein A4M induces robust RNAP II-dependent gene transcription by overwriting 396 
the elongation control process in a dominant fashion62-64. Since gene transcription per se and in particular 397 
“sterile” transcription is a powerful mechanism for chromatin activation, A4M could potentiate MA4 to skew 398 
normal and leukemic hematopoietic cell fate decisions. This also explains why MA4 has a more prominent 399 
role in the disease than the reciprocal A4M. If A4M functioned to initiate this process only by itself, then it 400 
would become obsolete after fulfilling the "chromatin opening job". However, transcription factors like MA4, 401 
RUNX1 or others then establish the transcriptional program leading to leukemogenesis. This is reflected in 402 
the enhanced hematopoietic potential of double fusion-expressing hESCs and the enriched H3K79me3 403 
activation mark in HOX-A cluster genes exclusively when MA4 and A4M are co-expressed. Thus, A4M 404 
prepares other transcription factors to become oncoproteins. 405 
 406 
Molecularly, C-terminal-partners of MLL fusions (AF4, AF9, ENL) interact with DOT1L, which is the sole 407 
histone methyltransferase catalyzing H3K79 methylation, a chromatin modification widely associated with the 408 
dysregulated expression of HOX-A gene cluster in MLL-rearranged leukemias13,53. Here, ChIP-seq analysis 409 
of differentially enriched H3K79me3 genomic regions confirmed a hematopoietic/endothelial cell 410 
differentiation signature in double fusion-expressing HEPs, and revealed a significant enrichment of H3K79 411 
methylated regions specifically associated with HOX-A cluster MLL target genes (but not to non-HOX-A MLL 412 
targets) in double fusion-expressing differentiating hematopoietic cells. This is in line with the recently found 413 
significant positive correlation between the upregulation of the HOX-A gene cluster and the expression of 414 
A4M in primary t(4;11)+ infant B-cell ALL samples, and with previous studies identifying that approximately 415 
one-half of t(4;11)+ patients do not have an activated HOX-A signature20,65,66. This may explain why MA4 416 
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failed recently to bind to HOX-A genes to regulate HOXA gene expression14. Collectively, MA4 and A4M 417 
might cooperate through a complex molecular interaction to control HOX-A gene regulation25. In sum, we 418 
describe a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic 419 
development, and demonstrate how hESC-based hematopoietic differentiation represents a promising 420 
system to explore the developmental impact of the chimeric proteins resulting from chromosomal 421 
translocations, which remains obscure in human leukemia. 422 
AUTHOR CONTRIBUTION: C.B. conceived the study, designed and performed experiments and analyzed 423 
data.  P.M. conceived the study, designed experiments, analyzed data and wrote the manuscript. F.C.N., 424 
X.W., R.V.M., F.G-A., H.R.H., V.A., P.J.R., D.A., L.E., R-T-R., A.A-D., J.dB. performed experiments and 425 
analyzed data. I.V., A.B., B.G., and R.M. contributed intellectually and financially. 426 
 427 
ACKNOWLEDGMENTS. Financial support for this work was obtained from the European Research Council 428 
(CoG-2014-646903 and PoC-2018-811220) and the Generalitat de Catalunya (SGR330 and PERIS 2017-429 
2019) to PM, the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF2016-430 
76758-R) to PM and IV, the Spanish Association against cancer (AECC-CI-2015) to CB, the Health Institute 431 
Carlos III (ISCIII/FEDER, PI17/01028 and PI17/01028) to CB and PJR, the NIHR GOSH BRC and Great 432 
Ormond Street Hospital Children's Charity to J.dB, and Bloodwise and Cancer Research UK to BG. RM and 433 
PM were also supported by the Deutsche José Carreras Leukämie Stiftung. PM also acknowledges financial 434 
support from the Obra Social La Caixa-Fundaciò Josep Carreras. R-T-R is supported by a fellowship from 435 
the Spanish Association of Cancer Research (AECC). RV-M is supported by a Torres Quevedo fellowship 436 
by Spanish Ministry of Science and Innovation (PTQ-16-08623). P.M is an investigator of the Spanish Cell 437 
Therapy cooperative network (TERCEL).  438 
 439 
19 
 
CONFLICT OF INTEREST DISCLOSURE: The authors have nothing to disclose. 440 
 441 
 442 
 443 
 444 
 445 
 446 
REFERENCES 447 
1. Milne TA. Mouse models of MLL leukemia: recapitulating the human disease. Blood. 448 
2017;129(16):2217-23. 449 
 450 
2. Montes R, Ayllon V, Prieto C, Bursen A, Prelle C, Romero-Moya D, et al. Ligand-independent FLT3 451 
activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells. Leukemia. 452 
2014;28(3):666-74. 453 
 454 
3. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, et al. Targeting FLT3 455 
in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005;106(7):2484-90. 456 
 457 
4. Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, et al. Revisiting the biology of 458 
infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood. 2015;126(25):2676-85. 459 
 460 
5. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC, et al. In utero rearrangements 461 
in the trithorax-related oncogene in infant leukaemias. Nature. 1993;363(6427):358-60. 462 
 463 
6. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 464 
2006;6(3):193-203. 465 
 466 
7. Bueno C, Montes R, Catalina P, Rodriguez R, Menendez P. Insights into the cellular origin and 467 
etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. Leukemia. 468 
2011;25(3):400-10. 469 
 470 
8. Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SE, et al. Mll-AF4 Confers 471 
Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development. Cell Rep. 472 
2016;16(4):1039-54. 473 
 474 
9. Bueno C, Ayllon V, Montes R, Navarro-Montero O, Ramos-Mejia V, Real PJ, et al. FLT3 activation 475 
cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs. Blood. 476 
2013;121(19):3867-78, S1-3. 477 
 478 
20 
 
10. Bueno C, Montes R, Melen GJ, Ramos-Mejia V, Real PJ, Ayllon V, et al. A human ESC model for 479 
MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. Cell Res. 480 
2012;22(6):986-1002. 481 
 482 
11. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T, et al. The AF4.MLL fusion 483 
protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood. 2010;115(17):3570-9. 484 
 485 
12. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model 486 
results in lymphoid and myeloid deregulation and hematologic malignancy. Blood. 2006;108(2):669-77. 487 
 488 
13. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles 489 
define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5):355-68. 490 
 491 
14. Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, et al. Instructive Role of MLL-Fusion 492 
Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016;30(5):737-493 
49. 494 
 495 
15. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, et al. A conditional model of MLL-496 
AF4 B-cell tumourigenesis using invertor technology. Oncogene. 2006;25(22):3093-103. 497 
 498 
16. Montes R, Ayllon V, Gutierrez-Aranda I, Prat I, Hernandez-Lamas MC, Ponce L, et al. Enforced 499 
expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell 500 
function and clonogenic potential but is not sufficient to initiate leukemia. Blood. 2011;117(18):4746-58. 501 
 502 
17. Tamai H, Miyake K, Takatori M, Miyake N, Yamaguchi H, Dan K, et al. Activated K-Ras protein 503 
accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia. 504 
2011;25(5):888-91. 505 
 506 
18. Kowarz E, Burmeister T, Lo Nigro L, Jansen MW, Delabesse E, Klingebiel T, et al. Complex MLL 507 
rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele. Leukemia. 2007;21(6):1232-508 
8. 509 
 510 
19. Agraz-Doblas A. Bueno C., Bashford-Rogers R., Anindita R., Schneider P., Bardini M., Ballerini P., 511 
Cazzaniga G., Moreno T., Revilla C., Gut M., De Lorenzo P., Valsecchi MG, Roberts I, Pieters R, Varela I.,  512 
Menendez P.,  Stam R.W. Unravelling the cellular origin and clinical prognosis markers of infant B-cell acute 513 
lymphoblastic leukemia using genome-wide analysis. Haematologica. 2019;in press. 514 
 515 
20. Trentin L, Giordan M, Dingermann T, Basso G, Te Kronnie G, Marschalek R. Two independent gene 516 
signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur J Haematol. 2009;83(5):406-19. 517 
 518 
21. Kumar AR, Yao Q, Li Q, Sam TA, Kersey JH. t(4;11) leukemias display addiction to MLL-AF4 but not 519 
to AF4-MLL. Leuk Res. 2011;35(3):305-9. 520 
 521 
22. Sanders DS, Muntean AG, Hess JL. Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias? 522 
Leuk Res. 2011;35(3):299-300. 523 
 524 
21 
 
23. Prieto C, Marschalek R, Kuhn A, Bursen A, Bueno C, Menendez P. The AF4-MLL fusion transiently 525 
augments multilineage hematopoietic engraftment but is not sufficient to initiate leukemia in cord blood 526 
CD34(+) cells. Oncotarget. 2017;8(47):81936-41. 527 
 528 
24. Rego EM, Pandolfi PP. Reciprocal products of chromosomal translocations in human cancer 529 
pathogenesis: key players or innocent bystanders? Trends Mol Med. 2002;8(8):396-405. 530 
 531 
25. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, et al. RUNX1 is a key target in t(4;11) 532 
leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 533 
2013;3(1):116-27. 534 
 535 
26. Menendez P, Bueno C, Wang L. Human embryonic stem cells: A journey beyond cell replacement 536 
therapies. Cytotherapy. 2006;8(6):530-41. 537 
 538 
27. Romero-Moya D, Santos-Ocana C, Castano J, Garrabou G, Rodriguez-Gomez JA, Ruiz-Bonilla V, 539 
et al. Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells 540 
Model of Coenzyme Q10 Deficiency. Stem Cells. 2017;35(7):1687-703. 541 
 542 
28. Menendez P, Vargas A, Bueno C, Barrena S, Almeida J, De Santiago M, et al. Quantitative analysis 543 
of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia. 2004;18(3):491-8. 544 
 545 
29. Ramos-Mejia V, Melen GJ, Sanchez L, Gutierrez-Aranda I, Ligero G, Cortes JL, et al. Nodal/Activin 546 
signaling predicts human pluripotent stem cell lines prone to differentiate toward the hematopoietic lineage. 547 
Mol Ther. 2010;18(12):2173-81. 548 
 549 
30. Wang L, Li L, Shojaei F, Levac K, Cerdan C, Menendez P, et al. Endothelial and hematopoietic cell 550 
fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. 551 
Immunity. 2004;21(1):31-41. 552 
 553 
31. Diehl F, Rossig L, Zeiher AM, Dimmeler S, Urbich C. The histone methyltransferase MLL is an 554 
upstream regulator of endothelial-cell sprout formation. Blood. 2007;109(4):1472-8. 555 
 556 
32. Hatzipantelis ES, Athanassiou-Metaxa M, Gombakis N, Tzimouli V, Taparkou A, Sidi-Fragandrea V, 557 
et al. Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in 558 
children with acute lymphoblastic leukemia. Acta Haematol. 2011;125(3):130-5. 559 
 560 
33. Menendez P, Catalina P, Rodriguez R, Melen GJ, Bueno C, Arriero M, et al. Bone marrow 561 
mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion 562 
gene. J Exp Med. 2009;206(13):3131-41. 563 
 564 
34. Ramos-Mejia V, Fernandez AF, Ayllon V, Real PJ, Bueno C, Anderson P, et al. Maintenance of 565 
human embryonic stem cells in mesenchymal stem cell-conditioned media augments hematopoietic 566 
specification. Stem Cells Dev. 2012;21(9):1549-58. 567 
 568 
35. Sanchez L, Gutierrez-Aranda I, Ligero G, Martin M, Ayllon V, Real PJ, et al. Maintenance of human 569 
embryonic stem cells in media conditioned by human mesenchymal stem cells obviates the requirement of 570 
exogenous basic fibroblast growth factor supplementation. Tissue Eng Part C Methods. 2012;18(5):387-96. 571 
22 
 
 572 
36. Bueno C, Montes R, Martin L, Prat I, Hernandez MC, Orfao A, et al. NG2 antigen is expressed in 573 
CD34+ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the 574 
target cell where leukemogenesis is triggered? Leukemia. 2008;22(8):1475-8. 575 
 576 
37. Castano J, Menendez P, Bruzos-Cidon C, Straccia M, Sousa A, Zabaleta L, et al. Fast and efficient 577 
neural conversion of human hematopoietic cells. Stem Cell Reports. 2014;3(6):1118-31. 578 
 579 
38. Munoz-Lopez A, Romero-Moya D, Prieto C, Ramos-Mejia V, Agraz-Doblas A, Varela I, et al. 580 
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into 581 
Pluripotency. Stem Cell Reports. 2016;7(4):602-18. 582 
 583 
39. Bueno C, Sardina JL, Di Stefano B, Romero-Moya D, Munoz-Lopez A, Ariza L, et al. Reprogramming 584 
human B cells into induced pluripotent stem cells and its enhancement by C/EBPalpha. Leukemia. 585 
2016;30(3):674-82. 586 
 587 
40. Giorgetti A, Castano J, Bueno C, Diaz de la Guardia R, Delgado M, Bigas A, et al. Proinflammatory 588 
signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. Exp Hematol. 589 
2017;45:85-93 e2. 590 
 591 
41. Menendez P, Wang L, Chadwick K, Li L, Bhatia M. Retroviral transduction of hematopoietic cells 592 
differentiated from human embryonic stem cell-derived CD45(neg)PFV hemogenic precursors. Mol Ther. 593 
2004;10(6):1109-20. 594 
 595 
42. Bueno C, Roldan M, Anguita E, Romero-Moya D, Martin-Antonio B, Rosu-Myles M, et al. Bone 596 
marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune 597 
properties and do not contribute to the pathogenesis of the disease. Haematologica. 2014;99(7):1168-75. 598 
 599 
43. Ramos-Mejia V, Navarro-Montero O, Ayllon V, Bueno C, Romero T, Real PJ, et al. HOXA9 promotes 600 
hematopoietic commitment of human embryonic stem cells. Blood. 2014;124(20):3065-75. 601 
 602 
44. Toscano MG, Navarro-Montero O, Ayllon V, Ramos-Mejia V, Guerrero-Carreno X, Bueno C, et al. 603 
SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic 604 
stem cells. Mol Ther. 2015;23(1):158-70. 605 
 606 
45. Bueno C, Montes R, Menendez P. The ROCK inhibitor Y-27632 negatively affects the 607 
expansion/survival of both fresh and cryopreserved cord blood-derived CD34+ hematopoietic progenitor 608 
cells: Y-27632 negatively affects the expansion/survival of CD34+HSPCs. Stem Cell Rev. 2010;6(2):215-23. 609 
 610 
46. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, Catalina P, et al. Deficiency in 611 
p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates 612 
leiomyosarcoma in vivo. Cancer Res. 2010;70(10):4185-94. 613 
 614 
47. Ayllon V, Bueno C, Ramos-Mejia V, Navarro-Montero O, Prieto C, Real PJ, et al. The Notch ligand 615 
DLL4 specifically marks human hematoendothelial progenitors and regulates their hematopoietic fate. 616 
Leukemia. 2015;29(8):1741-53. 617 
 618 
23 
 
48. Vodyanik MA, Slukvin, II. Hematoendothelial differentiation of human embryonic stem cells. Curr 619 
Protoc Cell Biol. 2007;Chapter 23:Unit 23 6. 620 
 621 
49. Bueno C, Montes R, de la Cueva T, Gutierrez-Aranda I, Menendez P. Intra-bone marrow 622 
transplantation of human CD34(+) cells into NOD/LtSz-scid IL-2rgamma(null) mice permits multilineage 623 
engraftment without previous irradiation. Cytotherapy. 2010;12(1):45-9. 624 
 625 
50. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, Macia A, et al. Human 626 
induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells 627 
regardless the site of injection. Stem Cells. 2010;28(9):1568-70. 628 
 629 
51. Vodyanik MA, Bork JA, Thomson JA, Slukvin, II. Human embryonic stem cell-derived CD34+ cells: 630 
efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. 631 
Blood. 2005;105(2):617-26. 632 
 633 
52. Prieto C, Stam RW, Agraz-Doblas A, Ballerini P, Camos M, Castano J, et al. Activated KRAS 634 
Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ 635 
HSPC But Is Insufficient to Initiate Leukemia. Cancer Res. 2016;76(8):2478-89. 636 
 637 
53. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, et al. AF10 regulates 638 
progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 639 
2014;26(6):896-908. 640 
 641 
54. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, et al. Aberrant 642 
chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 643 
2008;22(24):3403-8. 644 
 645 
55. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic 646 
mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330-7. 647 
 648 
56. Malouf C, Ottersbach K. The fetal liver lymphoid-primed multipotent progenitor provides the 649 
prerequisites for the initiation of t(4;11) MLL-AF4 infant leukemia. Haematologica. 2018. 650 
 651 
57. Peters DG, Klucher KM, Perlingeiro RC, Dessain SK, Koh EY, Daley GQ. Autocrine and paracrine 652 
effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice. 653 
Oncogene. 2001;20(21):2636-46. 654 
 655 
58. Ji J, Risueno RM, Hong S, Allan D, Rosten P, Humphries K, et al. Brief report: ectopic expression of 656 
NUP98-HOXA10 augments erythroid differentiation of human embryonic stem cells. Stem Cells. 657 
2011;29(4):736-41. 658 
 659 
59. Tan YT, Ye L, Xie F, Beyer AI, Muench MO, Wang J, et al. Respecifying human iPSC-derived blood 660 
cells into highly engraftable hematopoietic stem and progenitor cells with a single factor. Proc Natl Acad Sci 661 
U S A. 2018;115(9):2180-5. 662 
 663 
60. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 664 
2011;152(2):141-54. 665 
24 
 
 666 
61. Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. In vivo imaging of 667 
haematopoietic cells emerging from the mouse aortic endothelium. Nature. 2010;464(7285):116-20. 668 
 669 
62. Ahmad K, Scholz B, Capelo R, Schweighofer I, Kahnt AS, Marschalek R, et al. AF4 and AF4-MLL 670 
mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3. Oncotarget. 671 
2015;6(28):25784-800. 672 
 673 
63. Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, Meyer B, et al. The leukemogenic AF4-674 
MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia. 675 
2011;25(1):135-44. 676 
 677 
64. Muck F, Bracharz S, Marschalek R. DDX6 transfers P-TEFb kinase to the AF4/AF4N (AFF1) super 678 
elongation complex. Am J Blood Res. 2016;6(3):28-45. 679 
 680 
65. Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, et 681 
al. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in 682 
infants. Haematologica. 2013;98(6):937-44. 683 
 684 
66. Kuhn A, Loscher D, Marschalek R. The IRX1/HOXA connection: insights into a novel t(4;11)- specific 685 
cancer mechanism. Oncotarget. 2016;7(23):35341-52. 686 
 687 
 688 
  689 
25 
 
FIGURE LEGENDS 690 
Figure 1. Characterization of transgenic human ESCs expressing the reciprocal fusion A4M together 691 
with MA4. (A) RNA-seq and qRT-PCR validation revealed that ~45% (11/25) of the patients with t(4;11)+ B-692 
ALL do not express the reciprocal fusion A4M18. (B) Left, Phase-contrast morphology of representative 693 
colonies from each transgenic hESC line. Right, RT-PCR confirming expression of both fusions in 694 
undifferentiated hESCs. (C) qRT-PCR expression of the pluripotency genes OCT4, SOX2, NANOG, 695 
CRIPTO, and DNMT3B. (D) Representative FACS data confirming expression of the pluripotency surface 696 
makers SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. 697 
 698 
Figure 2. A4M cooperates with MA4 to accelerate human ESC/EB specification towards HEPs and 699 
subsequent hematopoietic differentiation. (A) Schematic of EB hematopoietic differentiation of hESCs 700 
and end-point analyses. (B) Upper left, specification into HEPs (CD31+CD34+CD45-) is accelerated in double 701 
fusion-expressing hESCs. Subsequent differentiation of HEPs into hematopoietic progenitors (upper right) 702 
and mature CD45+ blood cells (bottom left) is enhanced in double fusion-expressing HEPs. Bottom right, CFU 703 
read-out and scoring (pie charts) confirming an accelerated and enhanced hematopoietic progenitor potential 704 
from double fusion-expressing blood derivatives. (C) RT-PCR confirming stable expression of MA4 and A4M 705 
upon EB differentiation. (D) Neither MA4- nor double fusion-expressing blood derivatives display in vivo 706 
hematopoietic engraftment potential in irradiated NSG mice. Data are presented as mean±SEM from at least 707 
three independent experiments. *p<0.05. 708 
 709 
Figure 3. Co-expression of MA4 and A4M enhances hematopoietic differentiation of human ESCs in 710 
OP9 co-culture. (A) Experimental design of OP9-based hESC differentiation towards HEPs and further 711 
hematopoietic commitment of HEPs maintained in either liquid culture for 16 days or in MS5 co-culture for 712 
30 days. (B) Frequency of total CD45+ blood cells after 9 days in OP9 co-culture. (C,D) CD45-CD31+CD34+ 713 
26 
 
HEPs were FACS-purified at day 9 of OP9 co-culture and allowed to differentiate into CD45+ cells in liquid 714 
culture (C) or in MS5 co-culture (D). Data represent mean±SEM from independent experiments. 715 
  716 
Figure 4. Enhanced endothelial cell fate from HEPs co-expressing MA4 and A4M. (A) Scheme of HEPs 717 
endothelial differentiation and phenotypic characterization. (B) FACS-sorted HEPs from day 9 human ESC-718 
OP9 co-cultures were cultured in EGM2 medium for 5 days and analyzed by immunofluorescence for VE-719 
cadherin, eNOS and vWF. (C) Top, Endothelial-like structures were identified and quantified based on VE-720 
cadherin staining (white dotted-lined areas in B, top panel). Bottom, Frequency of CD45-CD31+CD144+ 721 
endothelial cells quantified by flow cytometry. (D) In vivo endothelial engraftment potential 722 
(HLA.ABC+CD31+CD144+CD45-) analyzed in bone marrow of NSG mice 8 weeks after transplantation of 723 
HEPs. Data presented as mean±SEM from 5 independent experiments. *p<0.05. 724 
 725 
Figure 5. Co-expression of MA4 and A4M significantly enhances the emergence of both endothelial 726 
and hemogenic HEPs. (A) Representative flow cytometry analysis of HEPs with hemogenic (CD45-727 
CD31+CD43+CD34dim/+) and endothelial (CD45-CD31+CD43-CD34++) potential. (B,C) A4M cooperates with 728 
MA4 to boost the emergence of both endothelial (B) and hemogenic (C) HEPs. Data presented as 729 
mean±SEM from 3 independent experiments. (D) Expression of RUNX1c and Ve-Cad in hemogenic and 730 
endothelial HEPs. * p<0.05 731 
 732 
Figure 6: Transcriptional transition towards a hematopoietic/endothelial gene signature in double 733 
fusion-expressing HEPs.  (A) Heatmap representation of hierarchical clustering of genes differentially 734 
expressed between EV-, single fusions- and double fusion-expressing HEPs. Each column represents a 735 
technical replicate from three independent experiments. (B,C) Statistically significant functional categories 736 
(B) and cancer/leukemia-associated biofunctions (C) identified using IPA on genes differentially expressed 737 
27 
 
in single fusions-, and double fusion-expressing HEPs relative to EV. They are ranked by z-score. Functional 738 
categories associated with “hematological system development and function” and “cardiovascular system 739 
development” are shown in bold. All significant biofunctions are associated with blood cell differentiation, 740 
homeostasis and migration/movement. 741 
 742 
Figure 7: H3K79 methylation profiles at genomic loci of MLL targets in MA4-, A4M- and double fusion-743 
expressing human ESC-derived blood derivatives. (A) GO enrichment of differential H3K79me3 peaks 744 
specific for double fusion-expressing cells. (B-C) Representative profiles for ChIP-seq using anti-H3K79me3 745 
antibody at genomic regions of typical non-HOXA (B) and HOXA MLL targets (C). 746 
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SUPPLEMENTARY LEGENDS AND METHODS 
Chromatin immunoprecipitation Sequencing  
One million day 15 hematopoietic differentiating hEB-derived cells were subjected to Chromatin 
Immunoprecipitation (ChIP) as described 1. Briefly, formaldehyde crosslinked cell extracts were 
sonicated using a Bioruptor (Diagenode) with a 0.5-min interval protocol to obtain DNA fragments of 
200–500 bp. The chromatin fraction was divided into three parts and incubated overnight with 2 g of 
anti-H3K4me3, anti-H3K79me3, or anti-H3 antibodies (Abcam) in RIPA buffer, and precipitated with 
protein A/G-Sepharose (Amersham). Cross-linkage of the co-precipitated DNA-protein complexes was 
reversed, and the DNA was sequenced at the CRG-CNAG Genomics Facility. Paired-end 50 bp ChIP-
seq data reads were generated using a HiSeq 2500 Illumina sequencer. Alignment and peak detection 
was performed using the ENCODE (phase-3) histone ChIP-seq pipeline specifications. Reads were 
aligned to the human reference genome (assembly hg19) using BWA2, removing all reads with a quality 
score <30. Peaks were called using MACS23 and whole cell extract samples as background samples. 
Differential analysis of histone mark peaks between experimental groups and the EV control group was 
performed using DiffBind4, with a False Discovery Rate (FDR) cut-off of 0.1. Peaks annotation and 
Gene Ontology (GO) enrichment were analyzed with ChIP-Enrich package in R4, using an FDR 
threshold of 0.1. ChIP-Seq data is deposited and available at Gene Expression Omnibus (GEO, 
accession number GSE111263). 
 
Low-input RNA-seq and bulk RNA-seq on t(4;11)+B-ALL patients 
For low-input RNAseq, 50 HEPs were FACS-purified from day 15 EBs into individual wells of a 96-well 
PCR plate containing lysis buffer (0.2% Triton-X100 and 2.3 U of SUPERase-In RNase Inhibitor; 
Ambion). Three independent replicates (50 cells/replicate) per condition were analyzed. RNA/cDNA 
was obtained and amplified as per the SMARTSEQ2 protocol5,6. Libraries were prepared for 
2 
 
sequencing using the Illumina Nextera XT DNA preparation kit. RNA-seq data was generated using a 
50 single-end sequencing protocol. Pooled libraries were sequenced on the Illumina HiSeq 4000 
platform. Reads were mapped to the human genome (Ensembl 81) and the ERCC sequences using 
STAR (version 2.4.2a) with default parameters. HTseq-count7 was used to count the number of reads 
mapped to each gene with -s no (non-strand specific mode). Data were normalized for sequencing 
depth using the size factor from the DESeq2 package (version 1.12.2)8. Low-input RNA-seq data is 
deposited and available at GEO (GSE118947). 
 
Bulk RNA-seq data on t(4;11)+ B-ALL patients was generated on the Illumina HiSeq 2500 platform 
using a 76 paired-end sequencing protocol and aligned to the human reference genome (hg19) using 
Tophat19. A gene was considered differentially expressed in MA4-A4M+ HEPs when it was >2-fold 
regulated (p<0.01) compared with the equivalent gene in EV-HEPs. Analysis of functional categories 
and biofunctions was performed with the genes differentially expressed using Ingenuity Pathway 
Analysis software (Ingenuity Inc., Redwood City, CA). Potential read pairs supporting the expression 
of MA4 and A4M fusion transcripts in patient samples were identified manually and with in-house 
written scripts as pairs in which each read aligned unambiguously to a different gene and which were 
compatible with the genomic breakpoints that were determined at the DNA level in all the samples. 
Additionally, RT-PCR with primers corresponding to AF4 exon3 and MLL exon 12 (exons contained in 
all predicted fusions) was performed in all the samples to confirm the expression of any potential 
isoform of the reciprocal fusion gene. The identity of the isoform was confirmed by capillary sequencing. 
Finally, the expression of each fusion gene was determined by qRT-PCR using primer pairs spanning 
the breakpoint between genes. RNA-seq data is deposited and available at GEO (accession number 
GSE111263). 
 
3 
 
 
SUPPLEMENTARY REFERENCES 
1. Guiu J, Bergen DJ, De Pater E, et al. Identification of Cdca7 as a novel Notch transcriptional 
target involved in hematopoietic stem cell emergence. J Exp Med. 2014;211(12):2411-2423. 
 
2. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 
Bioinformatics. 2009;25(14):1754-1760. 
 
3. Zhang Y, Liu T, Meyer CA, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 
2008;9(9):R137. 
 
4. Welch RP, Lee C, Imbriano PM, et al. ChIP-Enrich: gene set enrichment testing for ChIP-seq 
data. Nucleic Acids Res. 2014;42(13):e105. 
 
5. Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for 
sensitive full-length transcriptome profiling in single cells. Nat Methods. 2013;10(11):1096-1098. 
 
6. Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R. Full-length RNA-
seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171-181. 
 
7. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput 
sequencing data. Bioinformatics. 2015;31(2):166-169. 
 
8. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
seq data with DESeq2. Genome Biol. 2014;15(12):550. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
SUPPLEMENTARY LEGENDS 
Figure S1. Coding sequence of the A4M fusion used in this study. (A) The full-length cDNA was 
sequenced-verified. Fusion breakpoint is located in AF4 exon 2 and MLL exon 10. (B) Schematic of 
lentivectors used in this study. 
 
Figure S2. Co-expression of MA4 and A4M promotes specification rather than 
survival/proliferation of HEPs. (A) Day 20 MA4-expressing hEBs display a significant higher HEP 
production coupled to an impaired blood (CD45+ and CD45+CD34+) formation. (B) Left, representative 
FACS analysis of the identification of HEPs and CD45+ hematopoietic cells and their cell-cycle 
distribution. Right, frequency of proliferating (S+G2M phases) CD45+ blood cells and HEPs. (C) Left, 
representative FACS analysis of apoptotic CD45+ hematopoietic cells and HEPs. Right, frequency of 
apoptotic (Annexin V+) HEPs and CD45+ hematopoietic cells for the indicated genotypes. 
 
Figure S3. H3K79me3 ChIP-seq profiles for the different genotypes. (A) Correlation heatmap for 
both H3K79me3 and H3K4me3 using affinity scores based on read counts in consensus peaks 
distinguishes between the four experimental groups. (B) Venn diagrams depicting the number of 
differentially enriched genomic regions for H3K79me3 between experimental groups relative to EV. (C) 
Quantitative expression of the indicated HOX-A genes in CFUs from day 15 EV- and double-fusion-
expressing HEPs. 
 
Figure S4. H3K4me2 profiles at genomic loci of MLL targets identified by Guenther et al. 
Representative profiles for ChIP-seq using an anti-H3K4me3 antibody at genomic sites of HOX-A (A) 
and non-HOX (B) MLL targets in the indicated genotypes of human ESC-differentiating derivatives. 
Bueno C et al. Figure S1 
A 
AF4-MLL (8739 bp) 
Red: AF4 exon 1-3 
Blue: MLL exon 10 to 36 
ATG :Start Codon 
TAA :Stop Codon 
ATGGCAGCCCAGTCAAGTTTGTACAATGACGACAGAAACCTGCTTCGAATTAGAGAGAAGGAA
AGACGCAACCAGGAAGCCCACCAAGAGAAAGAGGCATTTCCTGAAAAGATTCCCCTTTTTGGA
GAGCCCTACAAGACAGCAAAAGGTGATGAGCTGTCTAGTCGAATACAGAACATGTTGGGAAAC
TACGAAGAAGTGAAGGAGTTCCTTAGTACTAAGTCTCACACTCATCGCCTGGATGCTTCTGAAA
ATAGGTTGGGAAAGCCGAAATATCCTTTAATTCCTGACAAAGGGAGCAGCATTCCATCCAGCT
CCTTCCACACTAGTGTCCACCACCAGTCCATTCACACTCCTGCGTCTGGACCACTTTCTGTTGG
CAACATTAGCCACAATCCAAAGATGGCGCAGCCAAGAACTGAACCAATGCCAAGTCTCCATGC
CAAAAGCTGCGGCCCACCGGACAGCCAGCACCTGACCCAGGATCGCCTTGGTCAGGAGGGG
TTCGGCTCTAGTCATCACAAGAAAGGTGACCGAAGAGCTGACGGAGACCACTGTGCTTCGGT
GACAGATTCGGCTCCAGAGAGGGAGCTTTCTCCCTTAATCTCTTTGCCTTCCCCAGTTCCCCC
TTTGTCACCTATACATTCCAACCAGCAAACTCTTCCCCGGACGCAAGGAAGCAGCAAGGTTCA
TGGCAGCAGCAATAACAGTAAAGGCTATTGCCCAGCCAAATCTCCCAAGGACCTAGCAGTGAA
AGTCCATGATAAAGAGACCCCTCAAGACAGTTTGGTGGCCCCTGCCCAGCCGCCTTCTCAGAC
ATTTCCACCTCCCTCCCTCCCCTCAAAAAGTGTTGCAATGCAGCAGAAGCCCACGGCTTATGT
CCGGCCCATGGATGGTCAAGATCAGGCCCCTAGTGAATCCCCTGAACTGAAACCACTGCCGG
AGGACTATCGACAGCAGACCTTTGAAAAAACAGACTTGAAAGTGCCTGCCAAAGCCAAGCTCA
CCAAACTGAAGATGCCTTCTCAGTCAGTTGAGGAGGATTGTGAAGCAGAAAATGTGTGGGAGA
TGGGAGGCTTAGGAATCTTGACTTCTGTTCCTATAACACCCAGGGTGGTTTGCTTTCTCTGTGC
CAGTAGTGGGCATGTAGAGTTTGTGTATTGCCAAGTCTGTTGTGAGCCCTTCCACAAGTTTTGT
TTAGAGGAGAACGAGCGCCCTCTGGAGGACCAGCTGGAAAATTGGTGTTGTCGTCGTTGCAA
ATTCTGTCACGTTTGTGGAAGGCAACATCAGGCTACAAAGCAGCTGCTGGAGTGTAATAAGTG
CCGAAACAGCTATCACCCTGAGTGCCTGGGACCAAACTACCCCACCAAACCCACAAAGAAGAA
GAAAGTCTGGATCTGTACCAAGTGTGTTCGCTGTAAGAGCTGTGGATCCACAACTCCAGGCAA
AGGGTGGGATGCACAGTGGTCTCATGATTTCTCACTGTGTCATGATTGCGCCAAGCTCTTTGC
TAAAGGAAACTTCTGCCCTCTCTGTGACAAATGTTATGATGATGATGACTATGAGAGTAAGATG
ATGCAATGTGGAAAGTGTGATCGCTGGGTCCATTCCAAATGTGAGAATCTTTCAGGTACAGAA
GATGAGATGTATGAGATTCTATCTAATCTGCCAGAAAGTGTGGCCTACACTTGTGTGAACTGTA
CTGAGCGGCACCCTGCAGAGTGGCGACTGGCCCTTGAAAAAGAGCTGCAGATTTCTCTGAAG
CAAGTTCTGACAGCTTTGTTGAATTCTCGGACTACCAGCCATTTGCTACGCTACCGGCAGGCT
GCCAAGCCTCCAGACTTAAATCCCGAGACAGAGGAGAGTATACCTTCCCGCAGCTCCCCCGA
AGGACCTGATCCACCAGTTCTTACTGAGGTCAGCAAACAGGATGATCAGCAGCCTTTAGATCT
AGAAGGAGTCAAGAGGAAGATGGACCAAGGGAATTACACATCTGTGTTGGAGTTCAGTGATGA
TATTGTGAAGATCATTCAAGCAGCCATTAATTCAGATGGAGGACAGCCAGAAATTAAAAAAGCC
AACAGCATGGTCAAGTCCTTCTTCATTCGGCAAATGGAACGTGTTTTTCCATGGTTCAGTGTCA
AAAAGTCCAGGTTTTGGGAGCCAAATAAAGTATCAAGCAACAGTGGGATGTTACCAAACGCAG
TGCTTCCACCTTCACTTGACCATAATTATGCTCAGTGGCAGGAGCGAGAGGAAAACAGCCACA
CTGAGCAGCCTCCTTTAATGAAGAAAATCATTCCAGCTCCCAAACCCAAAGGTCCTGGAGAAC
CAGACTCACCAACTCCTCTGCATCCTCCTACACCACCAATTTTGAGTACTGATAGGAGTCGAGA
AGACAGTCCAGAGCTGAACCCACCCCCAGGCATAGAAGACAATAGACAGTGTGCGTTATGTTT
GACTTATGGTGATGACAGTGCTAATGATGCTGGTCGTTTACTATATATTGGCCAAAATGAGTGG
ACACATGTAAATTGTGCTTTGTGGTCAGCGGAAGTGTTTGAAGATGATGACGGATCACTAAAGA
ATGTGCATATGGCTGTGATCAGGGGCAAGCAGCTGAGATGTGAATTCTGCCAAAAGCCAGGA
GCCACCGTGGGTTGCTGTCTCACATCCTGCACCAGCAACTATCACTTCATGTGTTCCCGAGCC
AAGAACTGTGTCTTTCTGGATGATAAAAAAGTATATTGCCAACGACATCGGGATTTGATCAAAG
GCGAAGTGGTTCCTGAGAATGGATTTGAAGTTTTCAGAAGAGTGTTTGTGGACTTTGAAGGAAT
CAGCTTGAGAAGGAAGTTTCTCAATGGCTTGGAACCAGAAAATATCCACATGATGATTGGGTCT
ATGACAATCGACTGCTTAGGAATTCTAAATGATCTCTCCGACTGTGAAGATAAGCTCTTTCCTAT
TGGATATCAGTGTTCCAGGGTATACTGGAGCACCACAGATGCTCGCAAGCGCTGTGTATATAC
ATGCAAGATAGTGGAGTGCCGTCCTCCAGTCGTAGAGCCGGATATCAACAGCACTGTTGAACA
TGATGAAAACAGGACCATTGCCCATAGTCCAACATCTTTTACAGAAAGTTCATCAAAAGAGAGT
CAAAACACAGCTGAAATTATAAGTCCTCCATCACCAGACCGACCTCCTCATTCACAAACCTCTG
GCTCCTGTTATTATCATGTCATCTCAAAGGTCCCCAGGATTCGAACACCCAGTTATTCTCCAAC
ACAGAGATCCCCTGGCTGTCGACCGTTGCCTTCTGCAGGAAGTCCTACCCCAACCACTCATGA
AATAGTCACAGTAGGTGATCCTTTACTCTCCTCTGGACTTCGAAGCATTGGCTCCAGGCGTCA
CAGTACCTCTTCCTTATCACCCCAGCGGTCCAAACTCCGGATAATGTCTCCAATGAGAACTGG
GAATACTTACTCTAGGAATAATGTTTCCTCAGTCTCCACCACCGGGACCGCTACTGATCTTGAA
TCAAGTGCCAAAGTAGTTGATCATGTCTTAGGGCCACTGAATTCAAGTACTAGTTTAGGGCAAA
ACACTTCCACCTCTTCAAATTTGCAAAGGACAGTGGTTACTGTAGGCAATAAAAACAGTCACTT
GGATGGATCTTCATCTTCAGAAATGAAGCAGTCCAGTGCTTCAGACTTGGTGTCCAAGAGCTC
CTCTTTAAAGGGAGAGAAGACCAAAGTGCTGAGTTCCAAGAGCTCAGAGGGATCTGCACATAA
TGTGGCTTACCCTGGAATTCCTAAACTGGCCCCACAGGTTCATAACACAACATCTAGAGAACTG
AATGTTAGTAAAATCGGCTCCTTTGCTGAACCCTCTTCAGTGTCGTTTTCTTCTAAAGAGGCCC
TCTCCTTCCCACACCTCCATTTGAGAGGGCAAAGGAATGATCGAGACCAACACACAGATTCTA
CCCAATCAGCAAACTCCTCTCCAGATGAAGATACTGAAGTCAAAACCTTGAAGCTATCTGGAAT
GAGCAACAGATCATCCATTATCAACGAACATATGGGATCTAGTTCCAGAGATAGGAGACAGAA
AGGGAAAAAATCCTGTAAAGAAACTTTCAAAGAAAAGCATTCCAGTAAATCTTTTTTGGAACCTG
GTCAGGTGACAACTGGTGAGGAAGGAAACTTGAAGCCAGAGTTTATGGATGAGGTTTTGACTC
CTGAGTATATGGGCCAACGACCATGTAACAATGTTTCTTCTGATAAGATTGGTGATAAAGGCCT
TTCTATGCCAGGAGTCCCCAAAGCTCCACCCATGCAAGTAGAAGGATCTGCCAAGGAATTACA
GGCACCACGGAAACGCACAGTCAAAGTGACACTGACACCTCTAAAAATGGAAAATGAGAGTCA
ATCCAAAAATGCCCTGAAAGAAAGTAGTCCTGCTTCCCCTTTGCAAATAGAGTCAACATCTCCC
ACAGAACCAATTTCAGCCTCTGAAAATCCAGGAGATGGTCCAGTGGCCCAACCAAGCCCCAAT
AATACCTCATGCCAGGATTCTCAAAGTAACAACTATCAGAATCTTCCAGTACAGGACAGAAACC
TAATGCTTCCAGATGGCCCCAAACCTCAGGAGGATGGCTCTTTTAAAAGGAGGTATCCCCGTC
GCAGTGCCCGTGCACGTTCTAACATGTTTTTTGGGCTTACCCCACTCTATGGAGTAAGATCCTA
TGGTGAAGAAGACATTCCATTCTACAGCAGCTCAACTGGGAAGAAGCGAGGCAAGAGATCAGC
TGAAGGACAGGTGGATGGGGCCGATGACTTAAGCACTTCAGATGAAGACGACTTATACTATTA
CAACTTCACTAGAACAGTGATTTCTTCAGGTGGAGAGGAACGACTGGCATCCCATAATTTATTT
CGGGAGGAGGAACAGTGTGATCTTCCAAAAATCTCACAGTTGGATGGTGTTGATGATGGGACA
GAGAGTGATACTAGTGTCACAGCCACAACAAGGAAAAGCAGCCAGATTCCAAAAAGAAATGGT
AAAGAAAATGGAACAGAGAACTTAAAGATTGATAGACCTGAAGATGCTGGGGAGAAAGAACAT
GTCACTAAGAGTTCTGTTGGCCACAAAAATGAGCCAAAGATGGATAACTGCCATTCTGTAAGCA
GAGTTAAAACACAGGGACAAGATTCCTTGGAAGCTCAGCTCAGCTCATTGGAGTCAAGCCGCA
GAGTCCACACAAGTACCCCCTCCGACAAAAATTTACTGGACACCTATAATACTGAGCTCCTGAA
ATCAGATTCAGACAATAACAACAGTGATGACTGTGGGAATATCCTGCCTTCAGACATTATGGAC
TTTGTACTAAAGAATACTCCATCCATGCAGGCTTTGGGTGAGAGCCCAGAGTCATCTTCATCAG
AACTCCTGAATCTTGGTGAAGGATTGGGTCTTGACAGTAATCGTGAAAAAGACATGGGTCTTTT
TGAAGTATTTTCTCAGCAGCTGCCTACAACAGAACCTGTGGATAGTAGTGTCTCTTCCTCTATC
TCAGCAGAGGAACAGTTTGAGTTGCCTCTAGAGCTACCATCTGATCTGTCTGTCTTGACCACC
CGGAGTCCCACTGTCCCCAGCCAGAATCCCAGTAGACTAGCTGTTATCTCAGACTCAGGGGA
GAAGAGAGTAACCATCACAGAAAAATCTGTAGCCTCCTCTGAAAGTGACCCAGCACTGCTGAG
CCCAGGAGTAGATCCAACTCCTGAAGGCCACATGACTCCTGATCATTTTATCCAAGGACACAT
GGATGCAGACCACATCTCTAGCCCTCCTTGTGGTTCAGTAGAGCAAGGTCATGGCAACAATCA
GGATTTAACTAGGAACAGTAGCACCCCTGGCCTTCAGGTACCTGTTTCCCCAACTGTTCCCAT
CCAGAACCAGAAGTATGTGCCCAATTCTACTGATAGTCCTGGCCCGTCTCAGATTTCCAATGCA
GCTGTCCAGACCACTCCACCCCACCTGAAGCCAGCCACTGAGAAACTCATAGTTGTTAACCAG
AACATGCAGCCACTTTATGTTCTCCAAACTCTTCCAAATGGAGTGACCCAAAAAATCCAATTGA
CCTCTTCTGTTAGTTCTACACCCAGTGTGATGGAGACAAATACTTCAGTATTGGGACCCATGGG
AGGTGGTCTCACCCTTACCACAGGACTAAATCCAAGCTTGCCAACTTCTCAATCTTTGTTCCCT
TCTGCTAGCAAAGGATTGCTACCCATGTCTCATCACCAGCACTTACATTCCTTCCCTGCAGCTA
CTCAAAGTAGTTTCCCACCAAACATCAGCAATCCTCCTTCAGGCCTGCTTATTGGGGTTCAGCC
TCCTCCGGATCCCCAACTTTTGGTTTCAGAATCCAGCCAGAGGACAGACCTCAGTACCACAGT
AGCCACTCCATCCTCTGGACTCAAGAAAAGACCCATATCTCGTCTACAGACCCGAAAGAATAAA
AAACTTGCTCCCTCTAGTACCCCTTCAAACATTGCCCCTTCTGATGTGGTTTCTAATATGACATT
GATTAACTTCACACCCTCCCAGCTTCCTAATCATCCAAGTCTGTTAGATTTGGGGTCACTTAATA
CTTCATCTCACCGAACTGTCCCCAACATCATAAAAAGATCTAAATCTAGCATCATGTATTTTGAA
CCGGCACCCCTGTTACCACAGAGTGTGGGAGGAACTGCTGCCACAGCGGCAGGCACATCAAC
AATAAGCCAGGATACTAGCCACCTCACATCAGGGTCTGTGTCTGGCTTGGCATCCAGTTCCTC
TGTCTTGAATGTTGTATCCATGCAAACTACCACAACCCCTACAAGTAGTGCGTCAGTTCCAGGA
CACGTCACCTTAACCAACCCAAGGTTGCTTGGTACCCCAGATATTGGCTCAATAAGCAATCTTT
TAATCAAAGCTAGCCAGCAGAGCCTGGGGATTCAGGACCAGCCTGTGGCTTTACCGCCAAGTT
CAGGAATGTTTCCACAACTGGGGACATCACAGACCCCCTCTACTGCTGCAATAACAGCGGCAT
CTAGCATCTGTGTGCTCCCCTCCACTCAGACTACGGGCATAACAGCCGCTTCACCTTCTGGGG
AAGCAGACGAACACTATCAGCTTCAGCATGTGAACCAGCTCCTTGCCAGCAAAACTGGGATTC
ATTCTTCCCAGCGTGATCTTGATTCTGCTTCAGGGCCCCAGGTATCCAACTTTACCCAGACGGT
AGACGCTCCTAATAGCATGGGACTGGAGCAGAACAAGGCTTTATCCTCAGCTGTGCAAGCCAG
CCCCACCTCTCCTGGGGGTTCTCCATCCTCTCCATCTTCTGGACAGCGGTCAGCAAGCCCTTC
AGTGCCGGGTCCCACTAAACCCAAACCAAAAACCAAACGGTTTCAGCTGCCTCTAGACAAAGG
GAATGGCAAGAAGCACAATGTTTCCCATTTGCGGACCAGTTCTTCTGAAGCACACATTCCAGA
CCAAGAAACGACATCCCTGACCTCAGGCACAGGGACTCCAGGAGCAGAGGCTGAGCAGCAG
GATACAGCTAGCGTGGAGCAGTCCTCCCAGAAGGAGTGTGGGCAACCTGCAGGGCAAGTCGC
TGTTCTTCCGGAAGTTCAGGTGACCCAAAATCCAGCAAATGAACAAGAAAGTGCAGAACCTAA
AACAGTGGAAGAAGAGGAAAGTAATTTCAGCTCCCCACTGATGCTTTGGCTTCAGCAAGAACA
AAAGCGGAAGGAAAGCATTACTGAGAAAAAACCCAAGAAAGGACTTGTTTTTGAAATTTCCAGT
GATGATGGCTTTCAGATCTGTGCAGAAAGTATTGAAGATGCCTGGAAGTCATTGACAGATAAAG
TCCAGGAAGCTCGATCAAATGCCCGCCTAAAGCAGCTCTCATTTGCAGGTGTTAACGGTTTGA
GGATGCTGGGGATTCTCCATGATGCAGTTGTGTTCCTCATTGAGCAGCTGTCTGGTGCCAAGC
ACTGTCGAAATTACAAATTCCGTTTCCACAAGCCAGAGGAGGCCAATGAACCCCCCTTGAACC
CTCACGGCTCAGCCAGGGCTGAAGTCCACCTCAGGAAGTCAGCATTTGACATGTTTAACTTCC
TGGCTTCTAAACATCGTCAGCCTCCTGAATACAACCCCAATGATGAAGAAGAGGAGGAGGTAC
AGCTGAAGTCAGCTCGGAGGGCAACTAGCATGGATCTGCCAATGCCCATGCGCTTCCGGCAC
TTAAAAAAGACTTCTAAGGAGGCAGTTGGTGTCTACAGGTCTCCCATCCATGGCCGGGGTCTT
TTCTGTAAGAGAAACATTGATGCAGGTGAGATGGTGATTGAGTATGCCGGCAACGTCATCCGC
TCCATCCAGACTGACAAGCGGGAAAAGTATTACGACAGCAAGGGCATTGGTTGCTATATGTTC
CGAATTGATGACTCAGAGGTAGTGGATGCCACCATGCATGGAAATGCTGCACGCTTCATCAAT
CACTCGTGTGAGCCTAACTGCTATTCTCGGGTCATCAATATTGATGGGCAGAAGCACATTGTCA
TCTTTGCCATGCGTAAGATCTACCGAGGAGAGGAACTCACTTACGACTATAAGTTCCCCATTGA
GGATGCCAGCAACAAGCTGCCCTGCAACTGTGGCGCTAAGAAATGCCGGAAGTTCCTAAACTA
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